Mechanisms of Disease: β-adrenergic receptors—alterations in signal transduction and pharmacogenomics in heart failure

[1]  Lluís Mont,et al.  Predictors of lack of response to resynchronization therapy. , 2005, The American journal of cardiology.

[2]  Julie A. Johnson,et al.  Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy. , 2005, Pharmacogenetics and genomics.

[3]  C. Stein,et al.  Pharmacogenetics and Response to β‐adrenergic Receptor Antagonists in Heart Failure , 2005, Clinical pharmacology and therapeutics.

[4]  P. Amouyel,et al.  Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure , 2005, Pharmacogenetics and genomics.

[5]  K. Adams,et al.  β‐adrenergic Receptor Polymorphisms and Responses during Titration of Metoprolol Controlled Release/extended Release in Heart Failure , 2005, Clinical pharmacology and therapeutics.

[6]  M. Esler,et al.  Interaction between cardiac sympathetic drive and heart rate in heart failure: modulation by adrenergic receptor genotype. , 2004, Journal of the American College of Cardiology.

[7]  S. Liggett.  Polymorphisms of β-adrenergic receptors in heart failure , 2004 .

[8]  H. Kroemer,et al.  Pharmacogenomics of heart failure -- focus on drug disposition and action. , 2004, Cardiovascular research.

[9]  M. Domanski,et al.  Effect of Baseline or Changes in Adrenergic Activity on Clinical Outcomes in the &bgr;-Blocker Evaluation of Survival Trial , 2004, Circulation.

[10]  W. Koch,et al.  Genetic manipulation of myocardial beta-adrenergic receptor activation and desensitization. , 2004, Journal of molecular and cellular cardiology.

[11]  R. Gainetdinov,et al.  G protein-coupled receptor kinase 5 regulates airway responses induced by muscarinic receptor activation. , 2004, American journal of physiology. Lung cellular and molecular physiology.

[12]  G. Dorn,et al.  Manipulating Cardiac Contractility in Heart Failure: Data From Mice and Men , 2004, Circulation.

[13]  E. Kranias,et al.  Phospholamban: A Promising Therapeutic Target in Heart Failure? , 2001, Cardiovascular Drugs and Therapy.

[14]  V. A. Skeberdis.  Structure and function of beta3-adrenergic receptors. , 2004, Medicina.

[15]  M. Böhm,et al.  Mechanisms of β-adrenergic receptor desensitization: from molecular biology to heart failure , 2004, Basic Research in Cardiology.

[16]  K. Lorenz,et al.  Protein kinase C switches the Raf kinase inhibitor from Raf-1 to GRK-2 , 2003, Nature.

[17]  K. Adams,et al.  Selective versus nonselective beta-blockade for heart failure therapy: are there lessons to be learned from the COMET trial? , 2003, Journal of cardiac failure.

[18]  S. Liggett,et al.  Pharmacology and physiology of human adrenergic receptor polymorphisms. , 2003, Annual review of pharmacology and toxicology.

[19]  Martin J. Lohse,et al.  What Is the Role of &bgr;-Adrenergic Signaling in Heart Failure? , 2003, Circulation research.

[20]  M. Domanski,et al.  A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. , 2003, Journal of cardiac failure.

[21]  G. Dorn,et al.  β1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure , 2003, Nature Medicine.

[22]  S. Ball,et al.  An evaluation of the beta‐1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT‐HF sub‐study , 2003, European journal of heart failure.

[23]  W. Abraham,et al.  Cardiac resynchronization therapy for advanced heart failure , 2003, Current treatment options in cardiovascular medicine.

[24]  Zhonglin Xie,et al.  β1 integrins expression in adult rat ventricular myocytes and its role in the regulation of β‐adrenergic receptor‐stimulated apoptosis , 2003 .

[25]  L. Luttrell,et al.  'Location, location, location': activation and targeting of MAP kinases by G protein-coupled receptors. , 2003, Journal of molecular endocrinology.

[26]  B. Kobilka,et al.  Linkage of beta1-adrenergic stimulation to apoptotic heart cell death through protein kinase A-independent activation of Ca2+/calmodulin kinase II. , 2003, The Journal of clinical investigation.

[27]  S. Harding,et al.  Evidence for protein phosphatase inhibitor‐1 playing an amplifier role in β‐adrenergic signaling in cardiac myocytes , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[28]  R. Quaife,et al.  Coordinate Changes in Myosin Heavy Chain Isoform Gene Expression Are Selectively Associated With Alterations in Dilated Cardiomyopathy Phenotype , 2002, Molecular medicine.

[29]  S. Kardia,et al.  Synergistic Polymorphisms of β1- and α2C-Adrenergic Receptors and the Risk of Congestive Heart Failure , 2002 .

[30]  Michael Böhm,et al.  Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol‐associated adverse effects , 2002, Clinical pharmacology and therapeutics.

[31]  W. Koch,et al.  Selective inhibition of heterotrimeric Gs signaling. Targeting the receptor-G protein interface using a peptide minigene encoding the Galpha(s) carboxyl terminus. , 2002, The Journal of biological chemistry.

[32]  T. Eschenhagen,et al.  Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment. , 2002, Pharmacogenetics.

[33]  Martin Biel,et al.  Cardiac HCN channels: structure, function, and modulation. , 2002, Trends in cardiovascular medicine.

[34]  R. Quaife,et al.  Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. , 2002, The New England journal of medicine.

[35]  U. Ravens,et al.  Physiological antagonism between ventricular β1‐adrenoceptors and α1‐adrenoceptors but no evidence for β2‐ and β3‐adrenoceptor function in murine heart , 2002 .

[36]  D. Sawyer,et al.  Adrenergic regulation of cardiac myocyte apoptosis , 2001, Journal of cellular physiology.

[37]  T. Kohout,et al.  Augmentation of Cardiac Contractility Mediated by the Human &bgr;3-Adrenergic Receptor Overexpressed in the Hearts of Transgenic Mice , 2001, Circulation.

[38]  M. Bristow,et al.  Inotropes and β-blockers: Is there a need for new guidelines? , 2001 .

[39]  S. Haunsø,et al.  G protein-coupled receptor kinase 2--a feedback regulator of Gq pathway signalling. , 2001, Current drug targets. Immune, endocrine and metabolic disorders.

[40]  J. Port,et al.  Altered beta-adrenergic receptor gene regulation and signaling in chronic heart failure. , 2001, Journal of molecular and cellular cardiology.

[41]  Physiological significance of beta-adrenergic receptor polymorphisms: in-vivo or in-vitro veritas? , 2001, Pharmacogenetics.

[42]  M. Cobb,et al.  Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. , 2001, Endocrine reviews.

[43]  John W. Adams,et al.  G-proteins in growth and apoptosis: lessons from the heart , 2001, Oncogene.

[44]  R. Lefkowitz,et al.  β-Arrestin 2: A Receptor-Regulated MAPK Scaffold for the Activation of JNK3 , 2000 .

[45]  E. Olson,et al.  Decoding calcium signals involved in cardiac growth and function , 2000, Nature Medicine.

[46]  M. Börjesson,et al.  A novel polymorphism in the gene coding for the beta(1)-adrenergic receptor associated with survival in patients with heart failure. , 2000, European heart journal.

[47]  R S Judson,et al.  Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[48]  M. Flesch,et al.  Different intrinsic activities of bucindolol, carvedilol and metoprolol in human failing myocardium , 2000, British journal of pharmacology.

[49]  D. Burkhoff,et al.  PKA Phosphorylation Dissociates FKBP12.6 from the Calcium Release Channel (Ryanodine Receptor) Defective Regulation in Failing Hearts , 2000, Cell.

[50]  R. Lefkowitz,et al.  Catecholamines, Cardiac b-Adrenergic Receptors, and Heart Failure , 2000 .

[51]  M. Bristow.  β-Adrenergic Receptor Blockade in Chronic Heart Failure , 2000 .

[52]  J. Granneman,et al.  β1-Adrenergic Receptors Mediate β3-Adrenergic-Independent Effects of CGP 12177 in Brown Adipose Tissue , 2000 .

[53]  M. Michel,et al.  Adrenergic and muscarinic receptors in the human heart. , 1999, Pharmacological reviews.

[54]  Catherine Communal,et al.  Opposing Effects of β1- and β2-Adrenergic Receptors on Cardiac Myocyte Apoptosis Role of a Pertussis Toxin–Sensitive G Protein , 1999 .

[55]  E. Lakatta,et al.  Recent Advances in Cardiac b2-Adrenergic Signal Transduction , 1999 .

[56]  M. Lohse,et al.  Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[57]  D. A. Mason,et al.  A Gain-of-function Polymorphism in a G-protein Coupling Domain of the Human β1-Adrenergic Receptor* , 1999, The Journal of Biological Chemistry.

[58]  W. Colucci.  The effects of norepinephrine on myocardial biology: Implications for the therapy of heart failure , 1998, Clinical cardiology.

[59]  T. McIntosh,et al.  The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. , 1998, The Journal of clinical investigation.

[60]  S. Green,et al.  Myocardial signaling defects and impaired cardiac function of a human beta 2-adrenergic receptor polymorphism expressed in transgenic mice. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[61]  R. Lefkowitz,et al.  Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or a beta ARK inhibitor. , 1995, Science.

[62]  R. Lefkowitz,et al.  Enhanced myocardial function in transgenic mice overexpressing the beta 2-adrenergic receptor. , 1994, Science.

[63]  M. Böhm,et al.  Expression of beta-arrestins and beta-adrenergic receptor kinases in the failing human heart. , 1994, Circulation research.

[64]  R. Lefkowitz,et al.  Enhanced Myocardial Function inTransgenic Mice Overexpressing theP2-Adrenergic Receptor , 1994 .

[65]  O. Brodde,et al.  Receptor systems affecting force of contraction in the human heart and their alterations in chronic heart failure. , 1992, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[66]  B. Parsons,et al.  Adrenergic Effects on the Biology of the Adult Mammalian Cardiocyte , 1992, Circulation.